Public Employees Retirement System of Ohio Reduces Holdings in IQVIA Holdings Inc. $IQV

Public Employees Retirement System of Ohio lowered its position in IQVIA Holdings Inc. (NYSE:IQV) by 40.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 50,899 shares of the medical research company’s stock after selling 33,964 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in IQVIA were worth $8,680,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in IQV. Ameliora Wealth Management Ltd. purchased a new position in shares of IQVIA in the fourth quarter worth about $25,000. Financial Freedom LLC bought a new position in IQVIA in the 1st quarter worth approximately $25,000. Ascentis Independent Advisors purchased a new position in IQVIA in the 1st quarter valued at approximately $25,000. International Assets Investment Management LLC purchased a new position in IQVIA in the 4th quarter valued at approximately $27,000. Finally, Gilpin Wealth Management LLC bought a new stake in IQVIA during the 4th quarter valued at $27,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Trading Up 2.3%

Shares of IQV stock opened at $212.76 on Tuesday. The company has a market capitalization of $35.51 billion, a PE ratio of 26.36, a price-to-earnings-growth ratio of 1.87 and a beta of 1.20. IQVIA Holdings Inc. has a 52-week low of $154.50 and a 52-week high of $247.04. The business’s fifty day moving average is $189.02 and its 200 day moving average is $186.85. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to analysts’ expectations of $4.10 billion. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The firm’s revenue was up 8.4% on a year-over-year basis. During the same period in the previous year, the business earned $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock buyback plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on IQV shares. Evercore reaffirmed an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Weiss Ratings upgraded IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Deutsche Bank Aktiengesellschaft set a $240.00 target price on IQVIA in a research note on Thursday, July 9th. Mizuho upped their price target on IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a research report on Monday, July 13th. Finally, Robert W. Baird increased their price target on shares of IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a report on Wednesday, July 1st. Thirteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $225.71.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.